World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
Journal website https://www.wjon.org |
Original Article
Volume 15, Number 4, August 2024, pages 640-647
Risk Stratification Tools to Aid Decisions on Adjuvant Chemotherapy Usage in Resected Soft Tissue Sarcomas: A Ten-Year Review of an Irish Sarcoma Center Experience
Figures
Tables
Variable | |
---|---|
FNCLCC: French Federation of Cancer Centers. | |
Median age, years (range) | 56.5 (18 - 87) |
Sex | |
Female | 31 (51.7%) |
Male | 29 (48.3%) |
Tumor size (median, mm), range | 60 (9 - 240) |
< 50 mm | 26 (43.3%) |
> 50 mm | 34 (56.7%) |
FNCLCC tumor grade | |
1 | 5 (8.3%) |
2 | 13 (21.7%) |
3 | 42 (70%) |
Location | |
Upper limb | 21 (35%) |
Lower limb | 31 (51.7%) |
Trunk | 8 (13.3%) |
Referral to oncology | 22 (36.7%) |
Chemotherapy | 7 |
Neoadjuvant | 4 |
Adjuvant | 3 |
Referral to radiation oncology | 44 |
Radiotherapy | 39 |
Neoadjuvant | 23 |
Adjuvant | 16 |
Median follow-up (months) | 49 (9 - 135) |
Histological subtypes | N |
---|---|
Adipocytic tumors | Dedifferentiated liposarcoma (n = 4) |
Pleomorphic liposarcoma (n = 3) | |
Myxoid liposarcoma (n = 2) | |
Fibroblastic/myofibroblastic tumors | Myxofibrosarcoma (n = 4) |
Fibromyxoid sarcoma (n = 2) | |
Inflammatory myofibroblastic tumor (n = 1) | |
Fibrosarcoma NOS (n = 1) | |
Vascular tumors | Angiosarcoma (n = 3) |
Epithelioid angiosarcoma (n = 1) | |
Smooth muscle tumors | Leiomyosarcoma (n = 12) |
Peripheral nerve sheath tumors | Malignant peripheral nerve sheath tumor (n = 3) |
Skeletal muscle tumors | Spindle cell sarcoma (n = 1) |
Pericytic (perivascular) tumors | PEComa (n = 1) |
Tumors of uncertain differentiation | Pleomorphic sarcoma, undifferentiated (n = 10) |
Synovial sarcoma (n = 5) | |
Epithelioid sarcoma (n = 3) | |
Undifferentiated sarcoma (n = 3) | |
Clear cell sarcoma (n = 1) | |
Myxoid sarcoma (n = 1) |
Sarculator score (risk assessment) | Patients, n | Deaths, n (%) | 5-year OS rate | |
---|---|---|---|---|
OS: overall survival; AJCC: American Joint Committee on Cancer. | ||||
High risk | 19 | 8 (42.1%) | 60.20% | P value = 0.009 |
Low risk | 41 | 6 (14.6%) | 87.10% | |
AJCC staging (risk assessment) | Patients, n | Deaths, n (%) | 5-year OS rate | |
High risk | 25 | 8 (32%) | 67.60% | P value = 0.083 |
Low risk | 35 | 6 (17%) | 86.30% |